New drug tested for Tough-to-Treat kidney cancer
NCT ID NCT05287945
Summary
This early-stage study is testing a drug called orellanine in people with advanced kidney cancer that has spread. The main goals are to find a safe dose and see if the drug can shrink tumors. The study is for patients who are already on regular dialysis and have run out of other treatment options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Karolinska University Hospital
RECRUITINGStockholm, Sweden
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Texas - MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University in St. Louis
RECRUITINGSt Louis, Missouri, 63130, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.